Clinical Trials
Discover the future of medicine today. Yale Medicine currently offers 688 active clinical trials across our hospitals and care centers, providing our patients with early access to many of the world’s most advanced therapies. Yale Center for Clinical Investigation (YCCI) supports, coordinates, and oversees clinical trials, ensuring the safety of trial volunteers.
For more information about cancer-related trials, call us at 203-785-5702. For all other trials, call 877-978-8343.
34 Results
JAKPOT T1D
- Diabetes
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors
- Prostate Cancer
- Bladder Cancer
Multi-center, parallel-group, randomized controlled trial of modified natural versus programmed cycles for frozen embryo transfers and their association with preeclampsia and live births (NatPro)
- Women's Health
- Gender:Female only
- Age:18 years - 41 years
A Phase 1 Study to Investigate PF-08046033 in Participants With Advanced Solid Tumors
- Stomach & Esophagus
- Lung Cancer
- Skin Cancers & Melanoma
A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
- Leukemia & Hematologic Cancers
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma
- Head & Neck Cancers
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Head & Neck Cancers
- Gender:All Genders
- Age:18 years and older
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
- Brain & Other Nervous System Cancers
Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas
- Brain & Other Nervous System Cancers
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
1-10 of 34 Results